Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next
Johnson & Johnson shares slipped 0.4% to $218.66 on Friday, the last session before U.S. markets shut for the Martin Luther King Jr. Day holiday.
Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land
Pfizer shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount, and key patents expire.
Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom
Pfizer Inc shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters.
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom
U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week.
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land
Shares of Pfizer Inc closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight.
Pfizer stock slips into long weekend as PFE investors line up earnings, dividend dates
Pfizer shares slipped 0.9% to close at $25.65 on Friday, just ahead of the U.S. market’s long weekend. Trading volume hit roughly 58 million shares.
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst
Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands.
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook
Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.
Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next
Shares of Pfizer climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector.
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus
Pfizer Inc shares climbed about 2% to $25.65 on Wednesday following CEO Albert Bourla’s remarks on the company’s push into the rapidly expanding cash-pay obesity drug market. “We are all in on obesity,” Bourla told reporters at the J.P. Morgan Healthcare Conference. Pfizer plans to launch 10 Phase 3 trials for its Metsera obesity compounds by the end of 2026, aiming to fuel future growth. The company still doesn’t expect revenue growth to return until 2029, as it navigates patent expirations and a slowdown in COVID-era sales.
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings
Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID.
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom
Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%.
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus
Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session.
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”
Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”
Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at up to $10 billion and has said it does not expect to return to revenue growth until 2029, closed down 0.8% at $25.27.
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next
Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday's premarket session.
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion
Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27.
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns
Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner Eliquis, and the American Hospital Association said it would have a “devastating effect.” Reuters
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk
Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS.
Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast
Pfizer said it will webcast a discussion with Chief Executive Albert Bourla at the J.P. Morgan Healthcare Conference next week, putting the drugmaker’s 2026 reset back in focus. Pfizer shares finished Monday little changed, down 0.04% at $25.17. Pfizer
TechStock² Updates
